Cancer treatments
AssigneeMayo Foundation for Medical Education and Research
InventorsSvetomir N. Markovic, Wendy K. Nevala
Life of this patent
Estimating the term…
Abstract
This invention relates to antibody-albumin nanoparticle complexes comprising albumin, an antibody with binding specificity for a cancer antigen (e.g. panitumumab), and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g. EGFR binding specificity), for the purpose of providing cancer (e.g. EGFR-related cancer) treatments in a subject in need thereof.
Claims18
1-72. (canceled)
A method for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, said complexes comprising albumin, a panitumumab antibody, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have EGFR binding specificity, wherein the cancer expresses EGFR, and wherein the average diameter of said complexes is between 0.1 μm and 1 μm.
An antibody-albumin nanoparticle complex comprising albumin, a panitumumab antibody, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with panitumumab under conditions to form the nanoparticle complex, such that the nanoparticle complex has EGFR binding specificity, and wherein the complex has a diameter of between 0.1 μm and 1 μm.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, said nanoparticle complexes comprising albumin, a panitumumab antibody, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have EGFR binding specificity, and wherein the average diameter of said complexes is between 0.1 μm and 1 μm.
Dependencies are inferred from the claim text.